[Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
Factor VIII (IX) inhibitors represent one of the most serious problems for the treatment of patients with hemophilia. The Blood Products Research Organization (Japan) has supported a study group for treatment of hemophiliacs with inhibitors. In 1995 the study group started a prospective matched control study of hemophiliacs with and without inhibitors and compared such factors as quality of life and economic cost. Each inhibitor patient was matched with a control patient in terms of age, type of hemophilia, and severity of hemophilia. A total of 136 patient-pairs were enrolled. Bleeding episodes were more frequent in the control group than in the inhibitor group. Days of hospitalization, days in wheelchairs, and the number of impaired joints were significantly higher for the inhibitor group. Number of blood-product infusions, days of bed rest at home, and days of brace use were the same for both groups. Blood-product expenditures were significantly higher for the inhibitor group than for the control group (yen 10,872,283/patient/year vs. yen 4,327,542/patient/year). Our study highlighted the higher cost of treatment and lower quality of life for hemophiliaes with Factor VII inhibitors.
K
K
Honda
T
T
Nagao
T
T
Kamiya
A
A
Yoshioka
T
T
Miyazaki
T
T
Takeda
K
K
Mori
K
K
Fukutake
H
H
Hanabusa
M
M
Taki
H
H
Mohri
J
J
Miyama
J
J
Takamatsu
S
S
Kinoshita
A
A
Shirahata
D000328:Adult; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000276:immunology*; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology*; D006467:Hemophilia A / Q000191:economics / Q000276:immunology* / Q000628:therapy*; D002836:Hemophilia B / Q000191:economics / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007518:Isoantibodies / Q000097:blood*; D011446:Prospective Studies; D011788:Quality of Life
D007518:Isoantibodies; D005169:Factor VIII; D005164:Factor IX